The market in sleeping pills, which took a nosedive after problems were reported with Halcion more than 10 years ago, appears to be experiencing a comeback, thanks in part to Sanofi-Aventis' drug Ambien. Now Sepracor is entering the market with Lunesta, which already has experienced strong demand, and three more sleeping pill applications are pending at the FDA.

Related Summaries